Published in Clin Infect Dis on May 17, 2006
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med (2012) 2.22
Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica (2009) 1.99
Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am (2011) 1.42
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med (2011) 1.32
Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs (2010) 1.31
Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2009) 1.12
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood (2011) 1.07
The occurrence and prevention of foodborne disease in vulnerable people. Foodborne Pathog Dis (2011) 1.06
Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy (2011) 1.02
Natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2009) 1.01
Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant (2009) 0.99
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant (2009) 0.99
Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev (2009) 0.96
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf (2012) 0.94
Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep (2014) 0.94
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia. BMC Infect Dis (2014) 0.85
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. Ther Clin Risk Manag (2014) 0.85
Current state of renal transplant immunosuppression: Present and future. World J Transplant (2012) 0.81
Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia. Emerg Infect Dis (2007) 0.80
Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS One (2012) 0.80
Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol (2016) 0.79
Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia. PLoS One (2013) 0.78
Infections associated with monoclonal antibody and fusion protein therapy in humans. MAbs (2011) 0.77
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord (2015) 0.76
Alemtuzumab and natalizumab: the monoclonal antibody story continues. Can J Infect Dis Med Microbiol (2006) 0.75
Immune Reconstitution Inflammatory Syndrome Occurring in a Kidney Transplant Patient with Extrapulmonary Tuberculosis. Case Rep Transplant (2017) 0.75
Molecularly targeted therapies for dysimmune neuropathies. Mol Med (2009) 0.75
Alemtuzumab in the up-front setting. Ther Clin Risk Manag (2008) 0.75
EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab. J Neurol (2010) 0.75
Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol (2012) 0.75
Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis. Clinicoecon Outcomes Res (2014) 0.75
Cytomegalovirus ventriculoencephalitis after unrelated double cord blood stem cell transplantation with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia. J Korean Med Sci (2010) 0.75
Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. J Immunol Res (2017) 0.75
Effect of alemtuzumab on intestinal intraepithelial lymphocytes and intestinal barrier function in cynomolgus model. Chin Med J (Engl) (2015) 0.75
Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab. Rheumatol Int (2007) 0.75
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med (2006) 5.42
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88
Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med (2011) 3.83
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med (2013) 3.39
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood (2012) 2.37
Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med (2004) 2.30
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol (2011) 2.26
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest (2005) 2.15
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol (2013) 2.06
Three patients with full facial transplantation. N Engl J Med (2011) 2.05
Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis (2010) 2.05
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood (2004) 2.01
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol (2005) 1.99
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2007) 1.99
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol (2002) 1.98
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood (2002) 1.97
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine (2006) 1.97
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood (2002) 1.92
FLT3 mutations in childhood acute lymphoblastic leukemia. Blood (2003) 1.91
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood (2008) 1.90
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol (2006) 1.88
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res (2005) 1.84
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA (2010) 1.82
Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol (2005) 1.82
International prognostic scoring system for Waldenstrom macroglobulinemia. Blood (2009) 1.81
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One (2011) 1.81
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood (2010) 1.79
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine (2007) 1.73
Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis (2008) 1.71
Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis (2009) 1.70
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol (2006) 1.68
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res (2009) 1.65
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol (2013) 1.63
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol (2007) 1.62
The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood (2013) 1.62
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A (2009) 1.61
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood (2013) 1.61
SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood (2011) 1.57
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol (2012) 1.55
Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med (2005) 1.55
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood (2007) 1.53
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res (2003) 1.51
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis (2005) 1.49
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis (2012) 1.47
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood (2013) 1.44
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma (2006) 1.44
Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol (2010) 1.43
Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res (2008) 1.42
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res (2004) 1.42
Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol (2011) 1.41
Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood (2012) 1.41
Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer (2010) 1.40
Recovery of Herbaspirillum species from persons with cystic fibrosis. J Clin Microbiol (2008) 1.39
Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood (2008) 1.36
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant (2006) 1.34
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 1.33
Preexposure prophylaxis for HIV--where do we go from here? N Engl J Med (2012) 1.33
Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology (2013) 1.32
Ebola and quarantine. N Engl J Med (2014) 1.32
H1N1 influenza A disease--information for health professionals. N Engl J Med (2009) 1.31
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood (2002) 1.31
Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program (2004) 1.29